ChondroFiller injection versus knee replacement for focal defectsChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
Who qualifies for ChondroFiller injectionChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.ChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.
ChondroFiller injection cost in the UKChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.ChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.
ChondroFiller injection for knee cartilage defectsThe injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.The injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.
Ultrasound-Guided ChondroFiller for Hip Cartilage DefectsAn injectable collagen scaffold recruits the patient's own cells to repair hip cartilage defects; clinical cohorts report 70–85% achieve meaningful symptom relief at 3–5 years, though success requires absence of pre-existing moderate-to-severe osteoarthritis.An injectable collagen scaffold recruits the patient's own cells to repair hip cartilage defects; clinical cohorts report 70–85% achieve meaningful symptom relief at 3–5 years, though success requires absence of pre-existing moderate-to-severe osteoarthritis.
ChondroFiller injection for talar osteochondral lesionsAn ultrasound-guided collagen scaffold injected in clinic, ChondroFiller recruits the patient's own progenitor cells to repair focal cartilage defects on the talar dome that persist despite at least six months of conservative care.An ultrasound-guided collagen scaffold injected in clinic, ChondroFiller recruits the patient's own progenitor cells to repair focal cartilage defects on the talar dome that persist despite at least six months of conservative care.
ChondroFiller injection versus cartilage surgeryChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.
What separates ChondroFiller from Liquid CartilageChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
ChondroFiller injection safety and the questions to askChondroFiller shows a near-zero complication rate across published trials and over 19,000 post-market cases; fibrous tissue forms only when the scaffold is overfilled, making precise dose determination from pre-procedure MRI the key safeguard.ChondroFiller shows a near-zero complication rate across published trials and over 19,000 post-market cases; fibrous tissue forms only when the scaffold is overfilled, making precise dose determination from pre-procedure MRI the key safeguard.
ChondroFiller versus hyaluronic acid for cartilage defectsChondroFiller fills discrete cartilage defects using a cell-recruiting scaffold; hyaluronic acid treats diffuse osteoarthritis through joint lubrication. They address different pathologies, and the choice depends on imaging, not on how much pain a patient experiences.ChondroFiller fills discrete cartilage defects using a cell-recruiting scaffold; hyaluronic acid treats diffuse osteoarthritis through joint lubrication. They address different pathologies, and the choice depends on imaging, not on how much pain a patient experiences.
ChondroFiller NHS status and private access routesChondroFiller is not available on the NHS, pending formal health technology assessment; private, self-funded treatment is the sole current UK access route.ChondroFiller is not available on the NHS, pending formal health technology assessment; private, self-funded treatment is the sole current UK access route.